RBC Capital Maintains Outperform on Edwards Lifesciences, Raises Price Target to $115
Benzinga Newsdesk 6 hours ago
Analyst RatingsNewsPrice TargetHot
RBC Capital analyst Kendall Au maintains Edwards Lifesciences (NYSE:EW) with a Outperform and raises the price target from $110 to $115.
RBC Capital analyst Kendall Au maintains Edwards Lifesciences (NYSE:EW) with a Outperform and raises the price target from $110 to $115.